Maxim Begins New Drug Study
Maxim Pharmaceuticals Inc. is trying again to win regulatory approval of a medicine previously rejected by the Food and Drug Administration by starting a new study of patients with advanced skin cancer.
The San Diego drug maker began a 224-patient trial designed to show that patients survive longer with its experimental compound Ceplene. The trial compares patients getting Ceplene and the approved treatment interleukin-2 with those getting IL-2 alone, Maxim said.
Maxim shares rose 23 cents to close at $6.35 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
